AMEX
| Health Care |
Biotechnology
Lineage Cell Therapeutics Inc. (LCTX)
LAST (4 Apr)
Extended HOURS (00:00 PM ET)
MARKET CAP
VOLUME
| Open | 0.42 |
| Previous Close | 0.4173 |
| Day Range | 0.40 - 0.44 |
| 52-Week Range | 0.40 - 1.56 |
| All-Time High | 24.94 |
| Avg. Volume (50-day) | 1,475,522.8 |
| EPS (TTM) | -0.0972 |
| Next Earnings Date | 2025-05-15 (AMC) |
| Last Earnings Date | 2025-03-10 |
| Forward Annual Dividend (Yield) | - |
| Trailing Annual Dividend (Yield) | - |
| Options | Yes |
| P/E Ratio | -4.2900 |
| PEG Ratio | 0.19 |
| Price to Book | 1.17 |
| Price to Cash Flow | - |
| Price to Free Cash Flow | - |
| Total Sales (TTM) | 9.50 M |
| Revenue per Share (TTM) | 0.04 |
| Shares Outstanding | 228.356 M |
| Share Float (%) | 227.36 M |
| % Held by Institutions | 51.09 |
| Dividends Per Share (TTM) | - |
| Ex-Dividend Date | - |
| +/- EMA(20) | 0.49 (-11.76%) |
| +/- SMA(50) | 0.58 (-25.45%) |
| +/- SMA(200) | 0.75 (-42.35%) |
| 5-Day Perf. | -12.1% |
| 1-Month Perf. | -18.84% |
| 3-Month Perf. | -26.72% |
| 6-Month Perf. | -52.48% |
| YTD Perf. | -13.95% |
| 1-Year Perf. | -69.97% |
| RSI(14) | 35.09 |
| ATR(14) | 0.04 |
| ADX(14) | 27.75 |
| Beta (5Y) | 1.07 |
FOR STOCKCHARTS MEMBERS ONLY
Unlock earnings and revenue history when you join StockCharts
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
LCTX
Lineage Cell Therapeutics Inc.
Sector: Health Care
Industry: Biotechnology
Employees: 77
Description
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
LCTX has triggered the following predefined scans:
| P&F Double Bottom Breakdown |
| P&F Descending Triple Bottom Breakdown |
| Elder Bar Turned Blue |
FOR STOCKCHARTS MEMBERS ONLY
Unlock custom technical alerts when you join StockCharts
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
FOR STOCKCHARTS MEMBERS ONLY
Unlock ChartLists to save and organize your charts when you join StockCharts
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.
